Leishmaniasis and various immunotherapeutic approaches
Leishmaniasis is a vector-borne infectious disease caused by multiple Leishmania (L.)
species with diverse clinical manifestations. There is currently no vaccine against any form …
species with diverse clinical manifestations. There is currently no vaccine against any form …
Visceral leishmaniasis: an overview of vaccine adjuvants and their applications
S Ratnapriya, AA Sahasrabuddhe, A Dube - Vaccine, 2019 - Elsevier
Although there has been an extensive research on vaccine development over the last
decade and some vaccines have been commercialized for canine visceral leishmaniasis …
decade and some vaccines have been commercialized for canine visceral leishmaniasis …
Nanoliposomal artemisinin for the treatment of murine visceral leishmaniasis
Visceral leishmaniasis (VL) is a fatal, vector-borne disease caused by the intracellular
protozoa of the genus Leishmania. Most of the therapeutics for VL are toxic, expensive, or …
protozoa of the genus Leishmania. Most of the therapeutics for VL are toxic, expensive, or …
Alternative to chemotherapy—The unmet demand against leishmaniasis
Leishmaniasis is a neglected protozoan disease that mainly affects the tropical as well as
subtropical countries of the world. The primary option to control the disease still relies on …
subtropical countries of the world. The primary option to control the disease still relies on …
A Chimera of Th1 Stimulatory Proteins of Leishmania donovani Offers Moderate Immunotherapeutic Efficacy with a Th1‐Inclined Immune Response against Visceral …
Immunotherapy, a treatment based on host immune system activation, has been shown to
provide a substitute for marginally effective conventional chemotherapy in controlling …
provide a substitute for marginally effective conventional chemotherapy in controlling …
Interferon inducible guanylate binding protein 1 restricts the growth of Leishmania donovani by modulating the level of cytokines/chemokines and MAP kinases
R Kumar, PK Kushawaha - Microbial Pathogenesis, 2022 - Elsevier
Visceral Leishmaniasis (VL) is a zoonotic chronic endemic infectious disease caused by
Leishmania donovani infection and a well-studied model for intracellular parasitism …
Leishmania donovani infection and a well-studied model for intracellular parasitism …
Immunomodulatory effects of adjuvants CPG, MPLA, and BCG on the Derp2-induced acute asthma at early life in an animal model of BALB/c Mice
Abstract The Th1-and Treg cell-related immune responses play key roles in the modulation
of Th2 cell-related allergic disorders. The aim was to evaluate the effects of CPG, MPLA, and …
of Th2 cell-related allergic disorders. The aim was to evaluate the effects of CPG, MPLA, and …
CpG-Adjuvanted Virus-like Particle Vaccine Induces Protective Immunity Against Leishmania donovani Infection
KW Yoon, KB Chu, GD Eom, J Mao… - The Journal of …, 2024 - academic.oup.com
Visceral leishmaniasis poses a significant public health challenge due to the lack of an
approved human vaccine. We attempted to enhance the efficacy of virus-like particle (VLP) …
approved human vaccine. We attempted to enhance the efficacy of virus-like particle (VLP) …
Interferon inducible guanylate‐binding protein 1 modulates the lipopolysaccharide‐induced cytokines/chemokines and mitogen‐activated protein kinases in …
R Kumar, PK Kushawaha - Microbiology and Immunology, 2024 - Wiley Online Library
Guanylate‐binding proteins (GBPs) are a family of interferon (IFN)‐inducible GTPases and
play a pivotal role in the host immune response to microbial infections. These are …
play a pivotal role in the host immune response to microbial infections. These are …
[HTML][HTML] Immunogenicity and efficacy of recombinant 78 kDa antigen of Leishmania donovani formulated in various adjuvants against murine visceral leishmaniasis
Objective To analyze the protective efficacy of recombinant 78 kDa antigen of Leishmania
donovani in combination with two adjuvants, that is, cationic liposomes or MPL-A against …
donovani in combination with two adjuvants, that is, cationic liposomes or MPL-A against …